3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
11
Lymphoid
10
Myeloid
3
Sarcoma
1
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
255
Myelodysplastic Syndromes
228
Leukemia, Myeloid, Acute
228
Anemia
212
Leukemia
205
Precursor Cell Lymphoblastic Leukemia-Lymphoma
168
Leukemia, Myelomonocytic, Chronic
145
Neoplasms
142
Leukemia, Lymphocytic, Chronic, B-Cell
116
Myeloproliferative Disorders
114
Multiple Myeloma
113
Lymphoma, Non-Hodgkin
105
Thrombocytopenia
100
Lymphoma
98
Hodgkin Disease
91
Anemia, Refractory
81
Venous Thromboembolism
77
Congenital Abnormalities
77
Anemia, Aplastic
77
Primary Myelofibrosis
76
Lymphoma, Follicular
73
Leukemia, Myeloid, Chronic-Phase
70
Blast Crisis
67
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65
Leukemia, Myeloid, Accelerated Phase
64
Lymphoma, Mantle-Cell
63
Febrile Neutropenia
62
Myelodysplastic-Myeloproliferative Diseases
58
Hematologic Neoplasms
56
Burkitt Lymphoma
56
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hemorrhagic Disorders
×
Classical hematology
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts